Journal
MOLECULAR BIOLOGY REPORTS
Volume -, Issue -, Pages -Publisher
SPRINGER
DOI: 10.1007/s11033-023-08461-x
Keywords
Mesenchymal stem cells; Osteoarthritis; Extracellular matrix; Type II collagen; Chondrogenic differentiation; Molecular targeting
Categories
Ask authors/readers for more resources
This study investigates the role of type II collagen in promoting chondrogenic differentiation in mesenchymal stem cells (MSCs). The results show that type II collagen enhances chondrogenesis in both Wharton's jelly and dental pulp-derived MSCs.
BackgroundOsteoarthritis (OA) is a common degenerative chronic disease accounting for physical pain, tissue stiffness and mobility restriction. Current therapeutic approaches fail to prevent the progression of the disease considering the limited knowledge on OA pathobiology. During OA progression, the extracellular matrix (ECM) of the cartilage is aberrantly remodeled by chondrocytes. Chondrocytes, being the main cell population of the cartilage, participate in cartilage regeneration process. To this end, modern tissue engineering strategies involve the recruitment of mesenchymal stem cells (MSCs) due to their regenerative capacity as to promote chondrocyte self-regeneration.Methods and resultsIn the present study, we evaluated the role of type II collagen, as the main matrix macromolecule in the cartilage matrix, to promote chondrogenic differentiation in two MSC in vitro culture systems. The chondrogenic differentiation of human Wharton's jelly- and dental pulp-derived MSCs was investigated over a 24-day culture period on type II collagen coating to improve the binding affinity of MSCs. Functional assays, demonstrated that type II collagen promoted chondrogenic differentiation in both MSCs tested, which was confirmed through gene and protein analysis of major chondrogenic markers.ConclusionsOur data support that type II collagen contributes as a natural bioscaffold enhancing chondrogenesis in both MSC models, thus enhancing the commitment of MSC-based therapeutic approaches in regenerative medicine to target OA and bring therapy closer to the clinical use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available